Alnylam to Webcast Presentations at Upcoming May Investor Conferences

Rhea-AI Summary

Alnylam Pharmaceuticals (Nasdaq: ALNY) revealed plans for management to present at two upcoming virtual conferences. The events are the BofA Health Care Conference on May 11, 2021, at 2:45 pm ET and the UBS Global Healthcare Virtual Conference on May 25, 2021, at 3:00 pm ET. Investors can access the live audio webcast on the company's website, with a replay available within 48 hours post-event. Alnylam is at the forefront of RNA interference therapeutics, focusing on innovative medicines for rare genetic and other diseases with a diverse pipeline of investigational products.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences which are being held virtually:

• BofA Health Care Conference on Tuesday, May 11, 2021 at 2:45 pm ET
• UBS Global Healthcare Virtual Conference on Tuesday, May 25, 2021 at 3:00 pm ET

A live audio webcast of each presentation will be available on the Investors section of the Company’s website at www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after each event.

About Alnylam

Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam’s commercial RNAi therapeutic products are ONPATTRO^® (patisiran), GIVLAARI^® (givosiran), OXLUMO^® (lumasiran), and Leqvio^® (inclisiran) being developed and commercialized by Alnylam’s partner Novartis. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P⁵x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam, on LinkedIn, or on Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210504005381/en/

FAQ

What conferences is Alnylam Pharmaceuticals participating in May 2021?

Alnylam Pharmaceuticals is participating in the BofA Health Care Conference on May 11, 2021, and the UBS Global Healthcare Virtual Conference on May 25, 2021.

What time will Alnylam present at the BofA Health Care Conference?

Alnylam will present at the BofA Health Care Conference on May 11, 2021, at 2:45 pm ET.

Where can I watch Alnylam's conference presentations?

You can watch Alnylam's conference presentations live on their Investors section of the website, with replays available within 48 hours after each event.

What does Alnylam Pharmaceuticals specialize in?

Alnylam specializes in RNA interference (RNAi) therapeutics, focusing on treatment options for rare genetic, cardio-metabolic, and other diseases.

What is Alnylam's commercial RNAi therapeutic product lineup?

Alnylam's commercial RNAi therapeutic products include ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), and Leqvio® (inclisiran).